Venmax Drugs & Pharmaceuticals Ltd
Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services[1]
- Market Cap ₹ 13.6 Cr.
- Current Price ₹ 26.0
- High / Low ₹ 30.9 / 0.00
- Stock P/E
- Book Value ₹ -2.75
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 23.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4.30 | 0.59 | 2.43 | 1.93 | 0.26 | 0.00 | 0.15 | 0.47 | 0.17 | 0.00 | 0.00 | 0.00 | 0.47 | |
4.91 | 1.02 | 2.54 | 2.07 | 0.88 | 0.23 | 0.38 | 0.72 | 0.50 | 0.12 | 0.19 | 0.11 | 1.32 | |
Operating Profit | -0.61 | -0.43 | -0.11 | -0.14 | -0.62 | -0.23 | -0.23 | -0.25 | -0.33 | -0.12 | -0.19 | -0.11 | -0.85 |
OPM % | -14.19% | -72.88% | -4.53% | -7.25% | -238.46% | -153.33% | -53.19% | -194.12% | -180.85% | ||||
0.00 | -1.32 | 0.00 | 0.00 | -0.72 | 0.00 | 0.00 | 0.00 | 0.18 | 1.98 | 0.42 | 0.20 | 0.13 | |
Interest | 0.17 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.25 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Profit before tax | -1.03 | -1.77 | -0.11 | -0.14 | -1.34 | -0.24 | -0.24 | -0.26 | -0.16 | 1.85 | 0.22 | 0.08 | -0.72 |
Tax % | -88.35% | 29.38% | -36.36% | 0.00% | 0.00% | 0.00% | 0.00% | 3.85% | 0.00% | 0.00% | 0.00% | 25.00% | |
-0.12 | -2.30 | -0.08 | -0.14 | -1.34 | -0.24 | -0.24 | -0.27 | -0.16 | 1.85 | 0.23 | 0.06 | -0.74 | |
EPS in Rs | -0.23 | -4.39 | -0.15 | -0.27 | -2.56 | -0.46 | -0.46 | -0.52 | -0.31 | 3.53 | 0.44 | 0.11 | -1.40 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 18% |
3 Years: | 33% |
TTM: | -452% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 |
Reserves | -2.52 | -4.82 | -4.90 | -5.04 | -7.11 | -7.35 | -7.59 | -7.86 | -8.03 | -6.18 | -5.95 | -5.89 | -6.18 |
4.19 | 1.40 | 1.50 | 1.72 | 1.85 | 2.04 | 2.24 | 2.52 | 2.33 | 0.35 | 0.35 | 0.35 | 0.35 | |
0.75 | 0.92 | 1.85 | 0.68 | 0.16 | 0.14 | 0.44 | 0.56 | 0.76 | 0.80 | 0.57 | 0.38 | 1.01 | |
Total Liabilities | 7.66 | 2.74 | 3.69 | 2.60 | 0.14 | 0.07 | 0.33 | 0.46 | 0.30 | 0.21 | 0.21 | 0.08 | 0.42 |
1.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.10 | 0.09 | 0.08 | 0.07 | 0.07 | 0.06 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
6.21 | 2.73 | 3.68 | 2.59 | 0.14 | 0.07 | 0.22 | 0.36 | 0.21 | 0.13 | 0.14 | 0.01 | 0.36 | |
Total Assets | 7.66 | 2.74 | 3.69 | 2.60 | 0.14 | 0.07 | 0.33 | 0.46 | 0.30 | 0.21 | 0.21 | 0.08 | 0.42 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.62 | 0.85 | -0.10 | -0.19 | -1.06 | -0.26 | -0.05 | -0.28 | 0.26 | 1.91 | 0.00 | 0.00 | |
0.00 | 1.43 | 0.00 | 0.00 | 0.01 | 0.00 | -0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
0.62 | -2.28 | 0.10 | 0.22 | 1.02 | 0.26 | 0.16 | 0.28 | -0.19 | -1.98 | 0.00 | 0.00 | |
Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.03 | -0.03 | 0.00 | 0.00 | 0.00 | 0.07 | -0.07 | 0.00 | 0.00 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 4.24 | 129.92 | 21.03 | 128.60 | 0.00 | 0.00 | 31.06 | 85.88 | ||||
Inventory Days | 57.99 | 468.30 | 225.44 | 0.00 | 0.00 | 446.11 | 250.94 | 0.00 | ||||
Days Payable | 34.96 | 75.75 | 251.51 | 1,257.22 | 456.25 | |||||||
Cash Conversion Cycle | 27.27 | 522.46 | -5.04 | 128.60 | 0.00 | -811.11 | -174.25 | 85.88 | ||||
Working Capital Days | -44.14 | 420.68 | -3.00 | 5.67 | -126.35 | -535.33 | -155.32 | -1,331.18 | ||||
ROCE % | -13.63% | -10.08% | -6.01% | -7.45% | -52.63% |
Documents
Announcements
-
Resignation Of Ms. Pratibha Jhawar From The Post Of Company Secretary & Compliance Officer
21 Apr - Company Secretary Pratibha Jhawar resigned effective April 21, 2025, accepted by the Board.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Compliance certificate for SEBI regulations submitted.
- Closure of Trading Window 28 Mar
-
Board Meeting Outcome for Allotment Of Equity Share Warrants.
21 Mar - Board approved allotment of equity share warrants.
-
Integrated Filing (Financial)
14 Feb - Integrated filing of financial results for Q3 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
a) VDPL is focused on establishing chain of Medical Stores with a brand name Ananya Pharma under the Venmax Drugs & Pharma Ltd, with the backing support of Formulations plant (Suzichem Labs). Currently, it has established 3 Shops & planning to expand them to 50 numbers around Hyderabad.
b) The company is developing oncology products in R&D. It is planning to establish a manufacturing UNIT with cGMP facility at Pharma Cluster at Hyderabad, to meet the export demand.